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Background
Tumors treated with doxorubicin generates immunogenic
cell death of tumor cells, favoring cross-presentation of
tumor antigens by DCs to CD8 T cells conferring antitu-
mor immunity in vaccinated mice. On the other hand,
low-dose of cyclophosphamide reduces the number of
regulatory T cells (Treg). Although treatment with doxor-
ubicin and cyclophosphamide (AC chemotherapy) is
widely used in patients with breast cancer, the immune-
stimulating effect of AC in these patients has been difficult
to prove.
Methodology
After signed informed consent, we compared in blood
samples from breast cancer patients obtained pre- and
post-chemotherapy several immunological parameters in
order to monitor changes in the response of T and APC
compartments during treatment. Using peripheral blood
samples of patients collected before and after three cycles
of AC we quantified by flow cytometry: (i) Tregs,
(ii) MDSCs; (iii) myeloid and plasmacytoid DCs; (iv) the
phenotype of Tumor Associated Antigens (TAAs) specific
T cells; and (v) the T cell activation and DC maturation
phenotype in response to TCR stimulation and to pro-
inflammatory cytokines respectively.
Results
We show a reversal of the suppression of T cell response
to polyclonal stimuli and maturation of DCs in response
to pro-inflammatory stimuli in samples from patients after
three cycles of chemotherapy not observed in the pre-
chemotherapy samples. Interestingly, in the same donor
the T cell response (TCR internalization) highly correlates
with IL-12 secretion by mature myeloid DC (CD83+).
Using factor analysis and Principal Component Analysis
(PCA), the data collected show significant differences
between the three categories analyzed (pre- vs. post-
chemotherapy patients and healthy donors).
Conclusions
The analysis of the different variables by PCA lead us to
argue for the capacity of chemotherapy to improve
responsiveness of the T and APC compartments in treated
patients to levels comparable to those of healthy controls
that was not observed in samples from untreated patients.
The application of this model of immune surveillance
required a careful optimization process using small sam-
ples of blood and brief periods of in vitro stimulation.
These interesting results must be validated with a larger
number of patients.
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